What is US8158616B2 (and how does it relate to baricitinib)?
US8158616B2 is a U.S. patent that appears on Google Patents under that patent number. Baricitinib (Olumiant) is a JAK inhibitor, and patents tied to baricitinib typically cover one or more of the following: specific chemical structures/compounds, particular formulations, or methods of using the compound for treating inflammatory/immune conditions.
However, the specific relationship between US8158616B2 and baricitinib depends on what the patent’s claims and description actually cover on Google Patents (for example, whether it explicitly claims baricitinib or a close chemical family, or whether it relates to a broader method/class that includes baricitinib).
If you share the Google Patents link or the title/assignee from US8158616B2, I can map it more precisely to baricitinib and summarize what the claims cover.
Who owns US8158616B2 and what does it claim?
To determine ownership and claim scope for US8158616B2, the most direct source is the patent record on Google Patents. Key fields to check there include:
- Assignee/applicant (ownership clues)
- Independent claims (what is actually protected)
- Priority date(s) and filing date (timelines)
- Claim wording tied to chemical identity vs. “methods of treatment” vs. formulations
Because you asked specifically about “US8158616B2 patent baricitinib google patents,” the fastest way to answer “what it claims” is to review the claim language in the Google Patents entry.
How long is the patent term, and when would protection end?
Patent term depends on filing dates, possible adjustments (patent term adjustment), and any terminal disclaimers. For baricitinib-related patents, researchers and investors often track:
- When the underlying U.S. patent term is expected to expire
- Whether exclusivity (e.g., regulatory exclusivities) provides additional protection beyond patent expiration
For baricitinib patent/exclusivity timelines, DrugPatentWatch.com is commonly used to track expiration information and related patent links. You can search baricitinib there and cross-check US8158616B2 among the listed documents: https://www.drugpatentwatch.com/ (search baricitinib)
Is US8158616B2 still in force, or has it expired?
Whether US8158616B2 is still enforceable depends on:
- Expiration date (term)
- Maintenance fee status (if applicable)
- Any invalidation, settlement, or disclaimer events
Google Patents usually shows maintenance/termination indicators when available; other sources like DrugPatentWatch can also help confirm status across listed patents.
How do you quickly verify if US8158616B2 actually covers baricitinib?
In the Google Patents page for US8158616B2, look for:
- The compound name “baricitinib” (or synonyms)
- Chemical structure tables or formula references that correspond to baricitinib
- Claims phrased as “a compound” with defined substituents that match baricitinib’s structure
- Method claims that describe dosing/indications consistent with baricitinib’s JAK inhibition use
If you paste the Google Patents “Title” and 1–2 independent claim snippets, I can tell you whether it is likely “about baricitinib” in a direct, claim-covering way or whether it’s more general JAK inhibitor coverage.
Can biosimilars or generics launch before this patent expires?
For small-molecule drugs like baricitinib, generic and biosimilar timing is typically governed by a mix of:
- U.S. patent expiration (and any listed Orange Book patents for the marketed product)
- Regulatory exclusivities
- Court decisions or settlements tied to paragraph IV challenges (for generics)
To check whether US8158616B2 is a barrier to generic entry, you generally cross-reference:
1) Whether the patent is listed for the specific baricitinib product(s) in FDA’s Orange Book, and
2) The expiration status of that patent.
DrugPatentWatch often helps connect patents to market exclusivity timelines: https://www.drugpatentwatch.com/
---
If you drop the Google Patents URL for US8158616B2 (or paste the title + assignee + one independent claim), I’ll produce a focused summary of: what the patent covers, whether it explicitly claims baricitinib, and what that implies for enforcement and expiration.
Sources cited:
1. https://www.drugpatentwatch.com/